Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

2.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

3.

FDA approves Blenrep for relapsed or refractory multiple myeloma

4.

Many Americans unaware of links between HPV and cancers, poll reveals

5.

Investigations may result in novel combination therapies for early-stage lung cancers.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot